Find Nafoxidine manufacturers, exporters & distributors on PharmaCompass

Nafoxidine

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1845-11-0, Nafoxidine [inn], Nafoxidinum [inn-latin], Nafoxidina [inn-spanish], 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine, U-11000a

Molecular Formula

C₂₉H₃₁NO₂

Molecular Weight

425.6 g/mol

InChI Key

JEYWNNAZDLFBFF-UHFFFAOYSA-N

FDA UNII

4RIY10WM82

An estrogen antagonist that has been used in the treatment of breast cancer.

1 2D Structure

Nafoxidine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine

2.1.2 InChI

InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3

2.1.3 InChI Key

JEYWNNAZDLFBFF-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5

2.2 Other Identifiers

2.2.1 UNII

4RIY10WM82

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Hydrochloride, Nafoxidine

2. Nafoxidine Hydrochloride

3. U 11,100a

4. U 11000a

5. U-11,100a

6. U-11000a

7. U11,100a

8. U11000a

2.3.2 Depositor-Supplied Synonyms

1. 1845-11-0

2. Nafoxidine [inn]

3. Nafoxidinum [inn-latin]

4. Nafoxidina [inn-spanish]

5. 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine

6. U-11000a

7. Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-

8. Chembl28211

9. 4riy10wm82

10. Chebi:34881

11. Nsc 70735

12. 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine

13. 1-(2-(4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy)ethyl)pyrrolidine

14. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine

15. Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)-

16. Pyrrolidine,1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]-

17. Nafoxidina

18. Nafoxidinum

19. Nsc70735

20. Brn 1440873

21. Unii-4riy10wm82

22. Spectrum5_000222

23. Nafoxidine [who-dd]

24. 5-20-01-00210 (beilstein Handbook Reference)

25. Bidd:er0063

26. Schembl153125

27. 11100a (*hydrochloride*)

28. Gtpl4263

29. Dtxsid7022386

30. U 11100 (*hydrochloride*)

31. U 11100a (*hydrochloride*)

32. U-11100a (*hydrochloride*)

33. Zinc538045

34. Bdbm50065941

35. Ncgc00188970-01

36. 845n110

37. Q6958201

38. 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)pyrrolidine

39. 1-(2-[4-(6-methoxy-2-phenyl-3,4-dihydro-1-naphthalenyl)phenoxy]ethyl)pyrrolidine #

40. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl}-pyrrolidine

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₁NO₂
Molecular Weight	425.6 g/mol
XLogP3	5.8
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	7
Exact Mass	425.235479232 g/mol
Monoisotopic Mass	425.235479232 g/mol
Topological Polar Surface Area	21.7 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	611
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

Estrogen Antagonists

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)

INTERMEDIATES SUPPLIERS